Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04662281 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT04662281 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT04662281, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
Interventions
- DRUG Placebo
- DRUG LX9211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04662281
The ClinicalTrials.gov registry entry for NCT04662281 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04662281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04662281 about?
NCT04662281 is a clinical study titled "Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia". Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
What is the current status of trial NCT04662281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2020-12-10. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT04662281?
The interventions under investigation include: Placebo (DRUG), LX9211 (DRUG).
Who is sponsoring clinical trial NCT04662281?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.